Advertisement

Topics

FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz

02:34 EST 14 Nov 2017 | RTTNews

Today's Daily Dose brings you news about expanded FDA approval for Allergan's schizophrenia drug; post-hoc analysis of Lilly's EMPA-REG OUTCOME trial; Court ruling against MediWound; extension of FDA's decision deadline by 3 months on Theratechnologies' biologics license application, TRACON's phase I data and Zymeworks' deal with Janssen Biotech.

Original Article: FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz

NEXT ARTICLE

More From BioPortfolio on "FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Schizophrenia
Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...